文献速递前列腺增生与排尿功能障碍

维贝格龙75mg每日一次治疗膀胱过度活动症的长期安全性与疗效:EMPOWUR国际3期双盲扩展研究

Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR).
PubMed 文献 · J Urol · 2020-12-28

EMPOWUR扩展研究评估维贝格龙75mg每日一次治疗膀胱过度活动症(OAB)的长期安全性、耐受性和疗效。505例患者接受双盲治疗,430例(85%)完成研究,因不良事件停药12例(2.4%)。52周时维贝格龙组在尿急尿失禁和总尿失禁 episodes 改善优于托特罗定(p<0.05),安全性良好。

要点

  • 维贝格龙75mg每日一次治疗OAB长期安全性良好,因不良事件停药率2.4%。
  • 52周时维贝格龙组尿急尿失禁较基线变化-2.2次 vs 托特罗定-1.7次(p<0.05)。
  • OAB湿性患者中61.0%维贝格龙组尿急尿失禁减少≥75%,托特罗定组54.4%。

核心结论

  • 维贝格龙75mg每日一次在OAB患者中展示良好的长期安全性、耐受性和疗效,与12周研究结果一致。

研究设计与样本

  • EMPOWUR国际3期双盲扩展研究,40周扩展期,纳入完成12周维贝格龙75mg或托特罗定4mg缓释片治疗的患者继续双盲治疗,安慰剂组按1:1随机分配至维贝格龙或托特罗定。
  • 506例患者随机,505例接受至少一剂药物,430例(85%)完成研究。

主要发现

  • 因不良事件停药12例(2.4%)。
  • 维贝格龙/托特罗定常见不良事件(任一组>5%):高血压8.8%/8.6%、尿路感染6.6%/7.3%、头痛5.5%/3.9%、鼻咽炎4.8%/5.2%、口干1.8%/5.2%。
  • 52周时排尿次数最小二乘均值变化:维贝格龙-2.4 vs 托特罗定-2.0;尿急尿失禁 episodes -2.2 vs -1.7(p<0.05);尿急 episodes -3.4 vs -3.2;总尿失禁 episodes -2.5 vs -1.9(p<0.05)。
  • OAB湿性患者中,维贝格龙组61.0%尿急尿失禁减少≥75% vs 托特罗定组54.4%;完全减少(100%)分别为40.8% vs 34.2%。

关键数值与推荐

  • 维贝格龙75mg每日一次,托特罗定4mg缓释片每日一次。
  • 主要结局为不良事件发生率;次要结局为第52周平均每日排尿次数、尿急 episodes、尿急尿失禁和总尿失禁 episodes 较基线变化(基于7天日记)。

临床怎么用

  • 维贝格龙可作为OAB的长期治疗选择,耐受性良好,尤其在尿急尿失禁改善方面可能优于托特罗定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The long-term safety, tolerability and efficacy of vibegron in adults with overactive bladder were evaluated in the 40-week phase 3 EMPOWUR extension study. MATERIALS AND METHODS: Patients who completed 12 weeks of once-daily vibegron 75 mg or tolterodine 4 mg extended release in EMPOWUR continued double-blind treatment; patients who completed 12 weeks of placebo were randomly assigned 1:1 to receive double-blind vibegron or tolterodine. The primary outcome was safety, measured by incidence of adverse events. Secondary outcomes included change from baseline at week 52 in average daily number of micturitions and urgency episodes (all patients), and urge and total urinary incontinence episodes (patients with overactive bladder wet) based on 7-day diary data. RESULTS: Of 506 patients randomized 505 received ≥1 dose of medication, and 430 (85%) completed the study. A total of 12 patients (2.4%) discontinued owing to adverse events. The most common adverse events with vibegron/tolterodine (>5% in either group) were hypertension (8.8%/8.6%), urinary tract infection (6.6%/7.3%), headache (5.5%/3.9%), nasopharyngitis (4.8%/5.2%) and dry mouth (1.8%/5.2%). Improvements in efficacy end points were maintained for patients receiving vibegron for 52 weeks; least squares mean change from baseline to week 52 in micturitions was ‒2.4 for vibegron vs ‒2.0 for tolterodine; in urge urinary incontinence episodes ‒2.2 vs ‒1.7 (p <0.05); in urgency episodes ‒3.4 vs ‒3.2; and in total incontinence episodes ‒2.5 vs ‒1.9 (p <0.05). Among patients with overactive bladder wet 61.0% receiving vibegron experienced ≥75% reduction in urge urinary incontinence episodes after 52 weeks of treatment vs 54.4% with tolterodine, while 40.8% vs 34.2% experienced a 100% reduction. CONCLUSIONS: Vibegron demonstrated favorable long-term safety, tolerability and efficacy in patients with overactive bladder, consistent with results of the 12-week study.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Staskin D, Frankel J, Varano S, et al. Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR). J Urol. 2020. PMID: 33356445. doi:10.1097/JU.0000000000001574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。